Hi5

Full title: 5HIAA as a marker for anti-vascular activity: change in serum 5HIAA in patients with advanced colorectal cancer receiving diclofenac or chemotherapy, and in control subjects without cancer receiving diclofenac
Cancer type: Colorectal
Status: Closed (29 participants recruited)
Brief description:

 

This was a pilot study where scientists and clinicians explored the clinical application of blood markers (serum 5HIAA) associated with endothelial damage during anti-cancer therapy. The study involves cancer patients who are planned to receive chemotherapy and a group of healthy volunteers.
Sites: Auckland
Lead Investigator: Professor Michael Findlay
Contact: Sarah Benge (s.benge@auckland.ac.nz)
Sponsor: University of Auckland
Funder: Genesis Oncology Trust
Trial Registry reference: ACTRN12605000459628 (click for more details)
Ethics number: AKY/04/11/315
Publications: